proxalutamide
Peptideexperimental
Proxalutamide is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of COVID-19, prostate cancer, and breast cancer. It was approved in Paraguay for the treatment of COVID-19 in July 2021, but has not been approved at this time in other countries. — Wikipedia
Clinical trial activity
12 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
10
Phase 3
7
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02826772)
Timeline
Indications
Mechanism of action
- Androgen ReceptorANTAGONIST
AR antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaProxalutamide ↗
Also known as
- proxalutamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05009732 | Phase 3 | Sep 30, 2021 | Suzhou Kintor Pharmaceutical Inc, |
| NCT04869228 | Phase 3 | Aug 4, 2021 | Hospital Santa Paula, Suzhou Kintor Pharmaceutical Inc, |
| NCT05076851 | Phase 2 | Jun 17, 2021 | Nanjing Medical University, Nanjing University |
| NCT05126628 | Phase 3 | Mar 6, 2021 | Corpometria Institute, Hospital Arcanjo Sao Miguel, Gramado, Brazil, Hospital da Brigada Militar de Porto Alegre, Porto Alegre, Brazil, Hospital Unimed Chapeco, Chapeco, Brazil |
| NCT04870606 | Phase 3 | Mar 5, 2021 | Suzhou Kintor Pharmaceutical Inc, |
| NCT04853927 | Phase 3 | Feb 8, 2021 | Applied Biology, Inc., Corpometria, Samel Hospital |
| NCT04728802 | Phase 3 | Feb 1, 2021 | Applied Biology, Inc. |
| NCT04853134 | Phase 3 | Nov 1, 2020 | Applied Biology, Inc., Corpometria Institute |
| NCT04446429 | N/A | Jul 2, 2020 | Applied Biology, Inc., Corpometria Institute |
| NCT03899467 | Phase 2 | May 30, 2019 | Suzhou Kintor Pharmaceutical Inc, |
| NCT04103853 | Phase 1 | Sep 6, 2017 | Central South University, Chinese Academy of Medical Sciences, Hebei University, Jiao Tong University, Nanjing Medical University, Sun Yat-Sen University, Suzhou Kintor Pharmaceutical Inc,, Tianjin Medical University |
| NCT02826772 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2016 | Suzhou Kintor Pharmaceutical Inc, |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Kintor Pharmaceutical Inc, | For profit | 6 | 6 | 3 | 2016 |
| Applied Biology, Inc. | For profit | 4 | 4 | 2 | 2020 |
| Corpometria Institute | Academic/Hospital | 3 | 1 | 2 | 2020 |
| Nanjing Medical University | Academic/Hospital | 2 | 0 | 2 | 2017 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Corpometria | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Hebei University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Hospital Arcanjo Sao Miguel, Gramado, Brazil | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Hospital da Brigada Militar de Porto Alegre, Porto Alegre, Brazil | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Hospital Santa Paula | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Hospital Unimed Chapeco, Chapeco, Brazil | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Nanjing University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Samel Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2017 |
17 organizations
Page 1 / 1